Z3 Capital Partners’s Apyx Medical APYX Stock Holding History

Z3 Capital Partners’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$409K	Sell	91,109 -1,950	-2%	-$7.73K	0.09%	130
2026 Q1	$343K	Buy	93,059 +3,000	+3%	+$11.2K	0.09%	137
2025 Q4	$315K	Buy	+90,059	New	+$314K	0.08%	147

Other funds holding APYX

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Z3 Capital Partners's APYX Position: Q2 2026 in Review

Z3 Capital Partners reduced its Apyx Medical (APYX) stake by 2.1% in Q2 2026, selling an estimated $7.73K and leaving 91,109 shares worth $409K. The position accounts for 0.09% of the portfolio, ranked #130.

Z3 Capital Partners first reported a position in APYX in Q4 2025 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

Z3 Capital Partners held 91,109 shares of Apyx Medical worth $409K as of Q2 2026.
Z3 Capital Partners sold 1,950 Apyx Medical shares in Q2 2026, an estimated $7.73K.
Apyx Medical made up 0.09% of Z3 Capital Partners's portfolio in Q2 2026, its #130 holding.
Z3 Capital Partners first reported a position in Apyx Medical in Q4 2025 and has held it in 3 quarters since.
65 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.